Healthcare
Latest Healthcare News
View MoreLatest Healthcare Analysis
View MoreCarl Icahn Ends Second Proxy Fight with Illumina (ILMN) Board
Activist investor Carl Icahn spares Illumina a second proxy contest, but continues lawsuit, leaving retail investors curious about board dynamics...
BSX AXNX: Boston Scientific Announces Pricing of €2 Billion Notes Offering
Boston Scientific Corp (BSX stock) announces €2 billion notes offering, financing strategic AXNX acquisition and providing investment opportunities.
Cardiol Therapeutics Receives Orphan Drug Designation for Pericarditis Treatment
Cardiol Therapeutics secures FDA ODD for pericarditis treatment, paving the way for innovative therapies and investment potential in this...
ALT Stock Short Report Raises Concerns over Altimmune's Weight-Loss Drug
Altimmune Inc. faces disappointment with its weight-loss drug, leading to a 19% stock drop. What does this mean for retail investors? Find out here.
Top Picks
View MoreTop Growth Stocks Q2 2022
Growth investing tends to be a medium to long-term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Growth Stocks Q1 2022
Growth investing tends to be a medium to long term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Momentum Stocks Q1 2022
Momentum investing tends to be a short-term investing strategy. Investors looking to buy shares in a stock look for signs of upward momentum and...
Q4 2021 Top Healthcare stocks to consider
Healthcare can be a lucrative investment area, but it's also a challenging sector to invest in. Here are some top health stocks in momentum, growth...
Press Releases
View MoreCardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research...
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, ON – November 1, 2023 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...